Tarlatamab's role in SCLC

WCLC 2026: Lung cancer research highlights

Harnessing AI and data to predict, personalise and transform cancer care

Izalontamab brenitecan shows promising activity in previously treated EGFR mutated NSCLC

Political prioritisation as a driver of vaccine introduction: Evidence from Nigeria’s HPV rollout

Multilevel factors shaping blinatumomab delivery across diverse LMICs

Zidesamtinib shows promising efficacy in TKI-naïve ROS1-positive advanced NSCLC

Isa-VRd shows sustained benefit in transplant-ineligible newly diagnosed multiple myeloma

Subcutaneous tarlatamab shows encouraging efficacy in previously treated extensive-stage SCLC

Pembrolizumab plus chemotherapy shows pathological responses in resectable pleural mesothelioma

Image-defined risk factors predict surgical outcomes in paediatric neuroblastic tumours

Subcutaneous tarlatamab shows promising safety and activity in previously treated extensive-stage SCLC